NMN vs NR (Nicotinamide Riboside): Which NAD+ Precursor Wins When the Head-to-Head Trials Disagree?

If you are comparing NMN and NR to pick the precursor that raises NAD+ "more," here is the honest headline: the two human studies that put them head-to-head reached opposite conclusions, so there is no settled winner. A tiny six-person crossover handed NR a big lead. A later, larger trial reported a tie. Most "NMN vs NR" pages quietly cite whichever trial flatters the product they sell. We do the opposite and lead with the conflict, because that disagreement is the most useful thing you can know before choosing.

Both compounds reliably raise blood NAD+, both were well tolerated in trials, and both feed the same salvage pathway. For the general science of what NAD+ is, IV-NAD, niacin, and sirtuins, we send you up to our hub on the complete NAD+ guide. This page stays narrow on one question: NR or NMN, which precursor, and what real people actually do when they have tried both. We add first-party community data no competitor page has, and we name the limitation of every trial we cite.

Key Takeaways

• There is no established human winner for "which raises NAD+ more." Two head-to-head trials disagree: a six-person crossover gave NR a large edge (+161% vs +67% whole-blood NAD+; Berven, iScience 2023), while a later, larger reported trial (n=65, 2026) found both roughly doubled NAD+ with no significant difference. Both reliably raise blood NAD+.
• NMN is "one step closer" to NAD+ on paper, but the shortcut is disputed. NMN is NR plus a phosphate and converts in one step via NMNAT, yet extracellular NMN may be dephosphorylated back to NR before cell entry, so the advantage may not survive biology (review PMC10240123, 2023).
• NR has the longer, larger evidence record. Its foundational human pharmacokinetic study showed a single 1,000 mg dose raised the blood NAD+ metabolome and steady dosing roughly doubled NAD+ (Trammell/Brenner, Nat Commun 2016).
• NMN holds the headline metabolic-outcome trial. 250 mg/day for 10 weeks improved muscle insulin sensitivity in prediabetic women (Yoshino, Science 2021).
• The cleanest real difference is regulatory. FDA excluded NMN from the supplement definition in November 2022, then reversed and declared it lawful again on September 30, 2025; NR's branded Niagen held clean NDI/GRAS status throughout.
• What our community does (ProtocolPlus app data): among users tracking these two, the split is about 54% NMN, 46% NR, roughly 22% co-track both, and the net switch flow is close to even (a slight net toward NMN). A usage signal, not an efficacy verdict.

Which raises NAD+ more, NMN or NR?

The one-sentence answer: nobody can say for sure, because the two human head-to-head trials reached opposite results. In a six-person crossover, NR raised whole-blood NAD+ by about 161% versus about 67% for NMN, a roughly 2.3x advantage (Berven et al., iScience 2023). In a later, larger reported trial of 65 people, both precursors roughly doubled NAD+ with no significant difference. That is the honest starting point.

Let me be specific about each study, because the limitations matter as much as the numbers. The first trial that favored NR (Berven et al., iScience 2023) dosed 1,200 mg/day of each compound for eight days in a crossover design, and the NR arm clearly outpaced the NMN arm on whole-blood NAD+. The catch is size: it enrolled only six participants at a single site, and the NMN arm was discontinued mid-study. A six-person result is a signal, not a verdict, and it is exactly the kind of small study that later, larger work often overturns.

The second trial points the other way. A reported 2026 study of 65 people, dosing 1,000 mg/day of each for 14 days, found both precursors roughly doubled blood NAD+ with no statistically significant difference between them. We flag this one as preliminary: it needs primary-source confirmation, so read it as "a later, larger trial reported parity" rather than a closed case. Put the two together and the only defensible claim is that both reliably raise blood NAD+, and no clear human winner is established.

The reason this matters is that the "which is stronger" question is the one brand pages exploit hardest. A vendor selling NR will quote the +161% figure as if it were a final score. A vendor selling NMN will reach for the parity trial or the metabolic-outcome study instead. Neither framing is honest on its own. The trials genuinely conflict, the larger one is preliminary, and the smaller one had six people. That is the real state of the evidence in 2026.

What is the actual pathway difference between NMN and NR?

The one-sentence answer: NMN is just NR with a phosphate group added, so on paper NMN is "one step closer" to NAD+, but that shortcut is disputed because extracellular NMN may be converted back to NR before it can enter a cell. Both ultimately feed the same NAD+ salvage pathway, and a 2023 review concludes neither route is cleanly proven superior in humans (review PMC10240123, 2023).

Here is the chemistry without the marketing. NR is converted to NAD+ in two enzymatic steps: NRK enzymes phosphorylate NR into NMN, then the enzyme NMNAT converts NMN into NAD+. NMN skips the first step, since it is already phosphorylated, and goes straight to NMNAT. That is the entire basis for the "one step closer" claim that NMN sellers lean on. As a pathway map, it is accurate.

The complication is cell entry. NMN is a larger, charged molecule, and a body of work suggests that extracellular NMN is often dephosphorylated to NR (by the enzyme CD73) before crossing the membrane, then re-phosphorylated back to NMN inside the cell. If that is the dominant route, the "shortcut" disappears, because NMN effectively becomes NR on the way in. A direct NMN transporter called Slc12a8 was proposed by the Imai lab in 2019, which would preserve the shortcut, but Brenner and colleagues published a rebuttal arguing the data did not support it, and its relevance in humans remains unresolved (Nature Metabolism 2019).

Why the CD73 dephosphorylation step matters

The phosphate that makes NMN "one step closer" is also what may strand it outside the cell. NMN carries a charged phosphate group, which makes the intact molecule a poor candidate to cross a cell membrane directly. A well-supported model holds that extracellular NMN is first dephosphorylated to NR by the surface enzyme CD73, the bare NR then crosses into the cell, and the cell re-phosphorylates it back to NMN with NRK enzymes before NMNAT finishes the job (review PMC10240123, 2023). If that loop is the main route, NMN spends part of its journey as NR.

That single step quietly collapses the marketing logic. If most ingested NMN becomes NR at the cell surface, then the "one fewer step" advantage is spent paying a toll NR never owed, and the two precursors converge on the same intracellular path. It does not make NMN worse, it just means the headline pathway diagram on a sales page is not the whole story. The shortcut exists on the chalkboard and may dissolve at the membrane.

The Slc12a8 transporter dispute, still unresolved

There is one scenario where NMN keeps its shortcut: a dedicated transporter that carries intact NMN straight into the cell. In 2019 the Imai lab reported exactly that, naming Slc12a8 as a direct NMN transporter, which, if real and relevant in humans, would let NMN bypass the CD73-to-NR detour entirely (Grozio/Imai, Nature Metabolism 2019). NMN proponents lean on this finding to defend the "one step closer" claim at the level of actual cell biology.

The finding did not stand unchallenged. Brenner and colleagues published a rebuttal arguing the data did not support a functional NMN transporter, and the dispute has never been cleanly resolved, least of all in humans, where its relevance is unconfirmed (Nature Metabolism 2019). So the honest status is a genuine open question: one lab says NMN has a private door into the cell, another says the door was never demonstrated. Until that is settled, no one can claim the NMN shortcut survives biology, and no one can rule it out either.

So what should you take from the pathway? Mostly this: the "one step closer" line is real on paper and uncertain in the body. Anyone presenting it as a settled mechanistic advantage for NMN is overstating what the science supports. Both compounds end up funneling through the same salvage machinery, and that shared bottleneck is part of why the head-to-head NAD+ results above are closer, and messier, than either marketing camp admits. For the deeper biology of NAD+ itself, see our NAD+ science hub.

What does the strongest human evidence actually show for each one?

The one-sentence answer: NR owns the longer, larger pharmacokinetic record, while NMN owns the single most-cited metabolic-outcome trial, and neither has human data showing it slows aging. NR's foundational study showed a single 1,000 mg dose raised the blood NAD+ metabolome with steady-state roughly doubling NAD+ (about 1.34x to 2.66x over baseline; Trammell/Brenner, Nat Commun 2016). That is the bedrock human data for either compound.

The two compounds built their cases differently, so it helps to take each one on its own terms. NR's strength is depth and replication of a pharmacokinetic effect. NMN's strength is one trial that moved a real clinical outcome, not just a blood marker. Below we lay out the actual studies behind each claim, with the dose, the duration, and the limitation, so you can weigh them yourself instead of trusting a brand's summary.

What does the NR human evidence show?

NR's case rests on the most-cited pharmacokinetic study in this whole field. In the foundational 2016 work, a single oral 1,000 mg dose of NR raised the human blood NAD+ metabolome, and repeat dosing pushed steady-state NAD+ to roughly 1.34x to 2.66x over baseline, in other words the rough doubling people quote (Trammell/Brenner, Nat Commun 2016). That single paper anchored the entire "NR raises NAD+ in people" claim and is still the reference point a decade later.

What followed matters as much as that first study. Since 2016, NR has accumulated a larger body of human safety and biomarker trials than NMN, across different doses and populations, repeatedly confirming the NAD+-raising effect rather than relying on one headline. This is the substance of NR's evidence edge. It is not that NR is proven to do more for your health. It is that its blood-NAD+ effect is simply better characterized in humans, with more independent confirmation behind it.

The honest limit is the same one that haunts NMN. None of NR's larger human record shows it slows aging, extends lifespan, or prevents disease. The trials establish a reliable biochemical effect (NAD+ goes up) and a clean tolerability profile, and they stop there. Anyone citing NR's "stronger evidence" as proof of an anti-aging benefit is stretching a pharmacokinetic and safety record into a clinical claim it does not make.

What does the NMN human evidence show?

NMN's case rests on outcomes, not just a marker, and that is genuinely different. In a randomized trial, 250 mg/day of NMN for 10 weeks in prediabetic postmenopausal women raised PBMC NAD+ and improved skeletal-muscle insulin sensitivity, a measured physiological change rather than a blood number (Yoshino et al., Science 2021). That is the single most-quoted NMN result, and it is the one fact that lets NMN advocates say their compound moved a clinical endpoint.

A second NMN trial adds modest functional signals. A randomized study in older men gave 250 mg/day for 12 weeks, raised blood NAD+, and reported small but statistically significant gains in gait speed (p=0.033) and grip strength (p=0.019), with no change in body composition (PMC9158788, 2022). Other reported NMN dosing in the 300 mg/day range over roughly 60 days describes blood NAD+ rising on the order of tens of percent over baseline, in line with the pattern that oral NMN reliably lifts blood NAD+ at these doses.

The honest read is that NMN's record is thinner but punchier. It has fewer total human trials than NR, yet it holds the one study people most want to cite, the Yoshino insulin-sensitivity result. The catch is the usual one: a 10-week change in a metabolic marker in prediabetic women is not evidence of slowed aging, and the older-men gains, while real, were modest. NMN has the better single headline; NR has the deeper file. Neither has the outcome that would actually settle the contest.

The honest read across the timeline is that both compounds clear the same low bar (they raise NAD+) and neither clears the high one (proven slowing of human aging). NR is better characterized; NMN has the one outcome study people quote most. If you are choosing on evidence strength alone, NR has the edge by volume. If you are choosing on the single most compelling outcome, NMN has the Yoshino trial. Neither edge is large enough to call the contest decisively.

Is NMN legal, and how does its FDA status differ from NR?

The one-sentence answer: this is the cleanest real difference between the two. In November 2022 the FDA said NMN was excluded from the dietary supplement definition; then on September 30, 2025 it reversed and declared NMN lawful in supplements again (nutraingredients, 2025). NR's branded form (Niagen) carried clean NDI and GRAS status throughout, so its supplement status was never in doubt.

Why did the FDA exclude NMN in 2022?

The NMN story is worth understanding because it is unusual, and it turns on a drug-preclusion rule. Under US law, an ingredient that was first studied as a drug under an investigational new drug (IND) application can be barred from later being sold as a dietary supplement. NMN had been investigated in that drug context, linked to the compound MIB-626, so in November 2022 the FDA took the position that NMN was excluded from the dietary supplement definition (nutraingredients, 2025). The clock of "drug first" beat the clock of "supplement first."

The fallout was immediate and practical. The exclusion created real uncertainty for sellers and buyers, some major retailers pulled NMN products from their shelves, and the legal status of a compound millions were already taking suddenly hung in question. None of this touched whether NMN raised NAD+ in trials. It was a pure regulatory-classification fight, and it is precisely the kind of fight NR never had to have.

What did the September 2025 reversal change?

The picture flipped on September 30, 2025. The FDA reversed its earlier stance and declared NMN lawful in dietary supplements again, removing the exclusion that had clouded the compound for nearly three years (nutraingredients, 2025). In plain terms, the agency that had said "NMN is not a supplement" now said it is, restoring NMN's lawful status and the ability to sell it openly in the US market.

One caveat keeps this honest. A further FDA follow-up dated December 2025 has been reported, but we have not confirmed it against the primary source, so we flag it as needing verification rather than building any conclusion on it. The settled, citable fact is the September 30, 2025 reversal. Anything dated after it should be checked directly with the FDA before you rely on it, and we will not overstate a follow-up we cannot yet stand behind.

How is NR's regulatory status different?

NR never went through any of that turbulence, and that is the cleanest single contrast on this whole page. Its branded form (Niagen) has carried New Dietary Ingredient (NDI) notification and Generally Recognized As Safe (GRAS) status throughout, so its right to be sold as a supplement was never in question across the same period NMN's was contested. While NMN's status swung from excluded to lawful between late 2022 and September 2025, NR simply held steady.

For most readers this is not about whether you can buy either one today, because you can buy both. It is about which has the steadier paper trail, and that is unambiguously NR. If regulatory predictability is something you weight, this is the one dimension where the two precursors genuinely diverge, and the gap favors NR even now that NMN is lawful again. For how legality interacts with quality and sourcing more broadly, see our guide to mitochondrial and NAD+ supplement sourcing.

What does the ProtocolPlus community actually do between NMN and NR?

The one-sentence answer: NMN is the slightly more-tracked of the two, a meaningful minority run both, and the switch traffic between them is close to even. Among users who log these two precursors, the split is about 54% NMN and 46% NR, roughly 22% co-track both, and the net switch flow is a near-even lean toward NMN. This is a usage signal, not an efficacy verdict, and everything below describes behavior, not a recommendation.

Three numbers carry the story, all from ProtocolPlus app data among the roughly 1,133 users tracking one of these two precursors:

• Adoption split: about 54% NMN (612 users), 46% NR (521 users). NMN is the slightly more-tracked of the pair, likely because the "one step closer to NAD+" framing is an easy sell and NMN has the headline metabolic-outcome study people share. The lead is modest, not lopsided.
• Co-tracking: about 22% (roughly 249 users) log both. A meaningful minority run NMN and NR together rather than choosing one, even though no human trial has tested the combination and both feed the same rate-limited salvage pathway.
• Net switch is close to even, a slight lean to NMN. About 19% of NR users (roughly 99) later moved to or added NMN, and about 14% of NMN users (roughly 86) moved the other way; the small net of about 13 users tilts toward NMN, a near one-to-one ratio. There is no decisive migration "winner."

A note on honesty about gaps: this supplement pair has no structured side-effect comparison and no per-dose cost data in our system, because both are well tolerated with few logged adverse events and pricing varies widely across brands and forms. We do not fabricate those numbers. The adoption, co-tracking, and switch direction are the parts we can stand behind, and they describe what people do, not which precursor is better.

The near-even switch flow is itself the most useful finding. With a clearly superior product you usually see a lopsided migration toward it. Here you do not. People drift both directions in roughly equal numbers, and a fifth of them simply run both. Read alongside the conflicting trials, that pattern fits the science: if there were an obvious NAD+-raising winner, the community would have voted with a stampede, and it hasn't.

Are NMN and NR safe, and what doses were studied?

The one-sentence answer: both were well tolerated in human trials, with a proposed upper intake around 900 mg/day for a 60 kg person, and the studied doses were modest (review PMC10240123, 2023). Human trials used 250 mg/day of NMN (Yoshino et al., Science 2021) and 1,000 mg of NR in the foundational pharmacokinetic work (Trammell/Brenner, Nat Commun 2016). These are doses used in studies, not a recommendation.

Tolerability looks similar for the two. Across the published human trials, both precursors produced few adverse events, and the side-effect profiles reported are mild and comparable. Neither has a documented serious-harm signal at studied doses, though long-term human safety data is still limited for both, and "well tolerated for weeks in a trial" is not the same as "proven safe for years of daily use." That gap is the honest caveat for either choice.

Is NMN or NR more bioavailable or stable?

On stability and absorption, the marketing claims outrun the data. Both NMN and NR are labile in blood, oral NMN is absorbed quickly and cleared from the bloodstream within about 15 minutes, and both depend on salvage-pathway flux rather than arriving intact at the target tissue (review PMC10240123, 2023). The rapid clearance is not a failure, it is the point: the precursor is meant to be pulled into the NAD+ salvage cycle, not to linger in plasma as the parent molecule.

That shared mechanism is why "more bioavailable" is the weakest of all the comparison claims. NR's foundational study showed it raised the NAD+ metabolome rather than persisting as intact NR in blood, and NMN behaves the same way (Trammell/Brenner, Nat Commun 2016). Both funnel through the same rate-limited salvage enzymes, so neither has a clean head-to-head stability or absorption advantage. A vendor claiming superior "stability" for either form is selling a distinction the human pharmacokinetic data does not support.

What doses were studied, and is there an upper limit?

The studied human doses were modest, not the megadoses some protocols push. NMN trials used 250 mg/day (Yoshino et al., Science 2021), and NR's foundational work used 1,000 mg as a single oral dose (Trammell/Brenner, Nat Commun 2016). A 2023 review proposes a tentative upper intake of around 900 mg/day for a 60 kg person, which is a directional ceiling derived from the literature, not a validated safety threshold (review PMC10240123, 2023). Treat it as a sensible upper bound, not a target.

These are doses used in studies, framed that way on purpose. None of them is a recommendation, and the absence of long-term human safety data for either compound means "studied for weeks" should not be read as "safe at any dose for years." If you have a medical condition or take medication, the dose question belongs with a clinician who knows your history, not with a label. For reported NAD+ precursor side effects in more detail, see our NAD+ side-effects guide.

What about cost and practicality?

Cost is a real-world factor that the trials cannot settle, so we keep this directional and avoid inventing numbers. In practice, branded NR (the Niagen form) and NMN both sell across a wide price range that depends on brand, purity certification, and dose per serving, with no stable head-to-head price that holds across the market. We do not have structured per-dose cost data for this pair in our system, so any single "X is cheaper" figure would be fabricated, and we will not provide one.

The practical takeaways that do hold are simpler. Both are taken orally, both at modest studied doses, and both feed the same pathway, so neither imposes a meaningfully different daily routine. The factors worth checking on a label are third-party purity testing and the actual amount per serving, not a marketing claim about stability or "superior" absorption. For how sourcing and quality interact more broadly, see our guide to mitochondrial and NAD+ supplement sourcing.

So which precursor should you pick?

The one-sentence answer: there is no evidence-based universal winner, so the choice comes down to which trade-off you weight, and the two are genuinely close. NR has the longer, larger human record and the steadier regulatory status; NMN has the one headline metabolic-outcome trial and the slight community lead. Both reliably raise blood NAD+, and neither is proven to slow human aging.

To make the trade-off concrete:

• Lean NR if you weight evidence depth and regulatory stability. It has the larger body of human pharmacokinetic and safety work (Trammell/Brenner, Nat Commun 2016), and its branded form held clean NDI/GRAS status while NMN's was contested from late 2022 to September 2025.
• Lean NMN if you weight the single best outcome trial and the pathway logic. It is the one with a human study showing improved muscle insulin sensitivity (Yoshino et al., Science 2021), and it is "one step closer" to NAD+ on paper, accepting that the shortcut is disputed.
• If your goal is anti-aging specifically: neither is proven, so the defensible move is modest expectations, a studied dose of one well-characterized precursor, and a clinician conversation, not a leap based on a marketing claim.
• If you are tempted to run both: the combination is unstudied in humans, both feed the same rate-limited pathway, and our community co-tracking share (about 22%) is a usage habit, not evidence it works better.

For where NAD+ precursors sit among the wider field of longevity compounds, see the best peptides and compounds for longevity. For the underlying biology, IV-NAD, and how niacin fits in, go up to the NAD+ hub. This page stays a decision hub and does not re-explain NAD+ science end to end.

Frequently Asked Questions

Sources

• Mehmel M, Jovanovic N, Spitz U, et al. "Nicotinamide Riboside - The Current State of Research and Therapeutic Uses" and related NAD+ precursor reviews. Nutrients / review PMC10240123, 2023. Pathway (NR to NMN to NAD+), disputed CD73/Slc12a8 cell-entry, lability and rapid clearance of both precursors, proposed ~900 mg/day upper intake. Retrieved 2026-06-22. https://pmc.ncbi.nlm.nih.gov/articles/PMC10240123/
• Grozio A, Mills KF, Yoshino J, et al. "Slc12a8 is a nicotinamide mononucleotide transporter." Nature Metabolism, 2019. Proposed direct NMN transporter; subsequently rebutted, human relevance unresolved. Retrieved 2026-06-22. https://www.nature.com/articles/s42255-019-0085-0
• Trammell SAJ, Schmidt MS, Brenner C, et al. "Nicotinamide riboside is uniquely and orally bioavailable in mice and humans." Nature Communications, 2016;7:12948. Single 1,000 mg dose raised the blood NAD+ metabolome; steady-state ~1.34x to 2.66x over baseline. Retrieved 2026-06-22. https://pmc.ncbi.nlm.nih.gov/articles/PMC5718430/
• Yoshino M, Yoshino J, Kayser BD, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science, 2021;372(6547):1224-1229. 250 mg/day NMN x 10 wk raised PBMC NAD+ and improved muscle insulin sensitivity. Retrieved 2026-06-22. https://www.science.org/doi/10.1126/science.abe9985
• Igarashi M, Nakagawa-Nagahama Y, Miura M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood NAD+ in healthy older men." npj Aging / PMC9158788, 2022. 250 mg/day NMN x 12 wk; modest gait-speed (p=0.033) and grip-strength (p=0.019) gains, no body-composition change. Retrieved 2026-06-22. https://pmc.ncbi.nlm.nih.gov/articles/PMC9158788/
• Berven H, Kverneng S, Sheard E, et al. "NR and NMN supplementation increases blood NAD+ in a crossover study." iScience, 2023. n=6 crossover, 1,200 mg/day each x 8 d: NR +161% vs NMN +67% whole-blood NAD+; NMN arm discontinued mid-study (small single-site sample). Retrieved 2026-06-22. https://www.cell.com/iscience/home
• Reported 2026 head-to-head trial (n=65, 1,000 mg/day each x 14 d): both precursors roughly doubled NAD+ with no significant difference. PRELIMINARY; flagged as needing primary-source confirmation, presented as a larger trial reporting parity rather than a settled result. Retrieved 2026-06-22.
• NutraIngredients-USA. "FDA declares NMN lawful in dietary supplements" (2025-09-30): FDA reversed its November 2022 exclusion of NMN from the supplement definition; NR's branded form (Niagen) carried clean NDI/GRAS status throughout. A December 2025 FDA follow-up exists; flagged as needing confirmation, not overstated. Retrieved 2026-06-22. https://www.nutraingredients.com/Article/2025/09/30/fda-declares-nmn-lawful-in-dietary-supplements/
• ProtocolPlus. "Community head-to-head data: NMN vs NR" (head-to-head/nmn__nr.json). First-party app data, 2026. n ~ 1,133 users tracking one of the two. Adoption ~54% NMN / ~46% NR; ~22% co-track both; near-even switch flow (slight net toward NMN). Usage and switching signal only; no side-effect or cost comparison available for this pair; not a clinical efficacy or safety verdict.